Radiotherapy developer Actinium Pharmaceuticals will present three abstracts accepted for poster presentation at the Society of Hematologic Oncology (SOHO) 2023 annual meeting in Houston, TX, between September 6 and 9.
Presentations will include the following:
- "The Randomized Phase III SIERRA (Study of Iomab-B in Elderly Relapsed or Refractory AML) Trial: Successful Allogeneic Hematopoietic Stem Cell Transplantation Using Treatment With Iomab-B-Led Regimen for Patients With Active, Relapsed or Refractory AML With Failed Targeted Therapies"
- "Sequential Salvage Chemotherapy and Lintuzumab-Ac225 in Relapsed/Refractory AML Results in Deep Responses and Prolonged Survival in Adverse Risk Acute Myeloid Leukemia (AML) and in AML Patients that Received Prior Venetoclax Therapy," and "Antileukemic Activity of Lintuzumab-Ac225 in Preclinical Model of FLT3 Mutant AML."
